Literature DB >> 33391155

Refractory Gilles de la Tourette Syndrome-Many Pieces That Define the Puzzle.

Natalia Szejko1,2,3, Adam Lombroso4, Michael H Bloch4, Angeli Landeros-Weisenberger4, James F Leckman4.   

Abstract

Gilles de la Tourette syndrome (GTS) is a childhood onset neuropsychiatric disorder characterized by the presence of motor and vocal tics. The clinical spectrum of GTS is heterogeneous and varies from mild cases that do not require any medical attention to cases that are refractory to standard treatments. One of the unresolved issues is the definition of what constitutes treatment-refractory GTS. While for some other neuropsychiatric disorders, such as obsessive-compulsive disorder (OCD), a clear definition has been established, there is still no consensus with regard to GTS. One important issue is that many individuals with GTS also meet criteria for one or more other neurodevelopmental and neuropsychiatric disorders. In many individuals, the severity of these comorbid conditions contributes to the degree to which GTS is treatment refractory. The scope of this paper is to present the current state-of-the-art regarding refractory GTS and indicate possible approaches to define it. In closing, we discuss promising approaches to the treatment of individuals with refractory GTS.
Copyright © 2020 Szejko, Lombroso, Bloch, Landeros-Weisenberger and Leckman.

Entities:  

Keywords:  Gilles de la Tourette syndrome; psychiatric comorbidities; severe tics; tics; treatment-refractoriness

Year:  2020        PMID: 33391155      PMCID: PMC7775596          DOI: 10.3389/fneur.2020.589511

Source DB:  PubMed          Journal:  Front Neurol        ISSN: 1664-2295            Impact factor:   4.003


  4 in total

Review 1.  The Rise of Functional Tic-Like Behaviors: What Do the COVID-19 Pandemic and Social Media Have to Do With It? A Narrative Review.

Authors:  Jaclyn M Martindale; Jonathan W Mink
Journal:  Front Pediatr       Date:  2022-07-11       Impact factor: 3.569

2.  Clinical characteristics of pediatric patients with treatment-refractory Tourette syndrome: An evidence-based survey in a Chinese population.

Authors:  Ying Li; Jun-Juan Yan; Yong-Hua Cui
Journal:  World J Psychiatry       Date:  2022-07-19

3.  Jing-an oral liquid alleviates Tourette syndrome via the NMDAR/MAPK/CREB pathway in vivo and in vitro.

Authors:  Leying Xi; Xixi Ji; Wenxiu Ji; Yue'e Yang; Yajie Zhang; Hongyan Long
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

Review 4.  European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part IV: deep brain stimulation.

Authors:  Natalia Szejko; Yulia Worbe; Andreas Hartmann; Veerle Visser-Vandewalle; Linda Ackermans; Christos Ganos; Mauro Porta; Albert F G Leentjens; Jan-Hinnerk Mehrkens; Daniel Huys; Juan Carlos Baldermann; Jens Kuhn; Carine Karachi; Cécile Delorme; Thomas Foltynie; Andrea E Cavanna; Danielle Cath; Kirsten Müller-Vahl
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-10-04       Impact factor: 4.785

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.